Zobrazeno 101 - 110
of 329
pro vyhledávání: '"Rita Nanda"'
Autor:
Hope S. Rugo, Javier Cortes, Binghe Xu, Chiun-Sheng Huang, Sung-Bae Kim, Michelle E. Melisko, Rita Nanda, Priyanka Sharma, Richard Schwab, Pei Hsu
Publikováno v:
Journal of Clinical Oncology. 40:TPS611-TPS611
TPS611 Background: Adagloxad simolenin (A-S) is an anti-Globo H immunogen comprised of the carbohydrate tumor antigen Globo H, covalently linked to keyhole limpet hemocyanin, a carrier protein that deploys T cells to enhance the humoral response. Adm
Autor:
Erika P. Hamilton, Anne F. Schott, Rita Nanda, Haolan Lu, Chi Fung Keung, Richard Gedrich, Janaki Parameswaran, Hyo S. Han, Sara A. Hurvitz
Publikováno v:
Journal of Clinical Oncology. 40:TPS1120-TPS1120
TPS1120 Background: ARV-471 is a novel, potent, orally bioavailable PROteolysis TArgeting Chimera (PROTAC) protein degrader that selectively targets the ER. In xenograft models, ARV-471 demonstrated substantially greater ER degradation and antitumor
Autor:
Sangeetha M. Reddy, Meredith Carter, Isaac Chan, Melanie Hullings, Nisha Unni, Jessica Medina, Shahbano Shakeel, Susan Armstrong, Lakeisha Cade, Farjana J. Fattah, Chul Ahn, Yisheng V. Fang, Nan Chen, Heather L. McArthur, Nicole Sinclair, Michael Jay Yellin, Joyce O'Shaughnessy, Rita Nanda, Suzanne D. Conzen, Carlos L. Arteaga
Publikováno v:
Journal of Clinical Oncology. 40:TPS1126-TPS1126
TPS1126 Background: Only a subset of patients with metastatic triple-negative breast cancer demonstrate response to currently approved PD-1 immune checkpoint blockade, and few have durable responses. Antigen presentation defects may be a reason for t
Autor:
Bryan P Schneider, Guanglong Jiang, Tarah J Ballinger, Fei Shen, Christopher Chitambar, Rita Nanda, Carla Falkson, Filipa C Lynce, Christopher Gallagher, Claudine Isaacs, Marcelo Blaya, Elisavet Paplomata, Radhika Walling, Karen Daily, Reshma Mahtani, Michael A Thompson, Robert Graham, Maureen E Cooper, Dean C Pavlick, Lee A Albacker, Jeffery Gregg, Jeffery P Solzak, Yu-Hsiang Chen, Casey L Bales, Erica Cantor, Bradley A Hancock, Nawal Kassem, Paul Helft, Bert O'Neil, Anna Maria Storniolo, Sunil Badve, Kathy D Miller, Milan Radovich
Publikováno v:
Cancer Research. 82:PD9-10
Purpose: Patients with triple negative breast cancer (TNBC) with residual disease after neoadjuvant chemotherapy (NAC) have high risk of recurrence with prior data suggesting improved outcomes with capecitabine. Targeted agents have demonstrated acti
Autor:
Frederick M. Howard, Gong He, John R Pfeiffer, Joseph R Peterson, John A. Cole, Alexander T. Pearson, Hiroyuki Abe, Rita Nanda
Publikováno v:
Cancer Research. 82:P4-05
Background: Pathological complete response (pCR) is a well validated endpoint for early-stage breast cancer (EBC) patients treated with neoadjuvant chemotherapy (NAT), with a strong correlation with long term outcomes such as event free survival (EFS
Autor:
Lowell L. Hart, Michelle Demeo, Minetta C. Liu, P. Kelly Marcom, Ron Bose, Douglas Weckstein, Ann H. Partridge, Blair Ardman, A. Merrill Garrett, Rita Nanda, Catherine Van Poznak, Andres Forero-Torres, Vicente Valero, Hope S. Rugo, Jiani Hu, Dan Sayam Zuckerman, Yue Zheng, Sara M. Tolaney, Eric P. Winer, Nabihah Tayob, Katherine E. Reeder-Hayes, Kit Cheng, Harold J. Burstein, Chau T. Dang, Patricia DeFusco, Vijayakrishna K. Gadi, Ian E. Krop, Therese M. Mulvey, Bryan P. Schneider, Rachel C. Jankowitz, Mothaffar F. Rimawi, Frederick Briccetti, Shoshana M. Rosenberg, Kathryn J. Ruddy, Nadine Tung, Vandana G. Abramson, Steven J. Isakoff, Tal Sella, Meredith Faggen, Bhuvaneswari Ramaswamy, Antonio C. Wolff, Paula R. Pohlmann, Michael Constantine, Kathy S. Albain, Denise A. Yardley
Publikováno v:
Breast cancer research and treatment. 189(1)
Chemotherapy-related amenorrhea (CRA) is a surrogate for ovarian toxicity and associated risk of infertility and premature menopause. Here, we compare CRA rate with paclitaxel (T)-trastuzumab (H) to that with ado-trastuzumab emtansine (T-DM1). Patien
Autor:
Jason J. Luke, Peter H. O'Donnell, Robyn D. Hseu, Everett E. Vokes, Mark D. Hoffman, John W. Moroney, Steven J. Chmura, Corey C. Foster, Ralph R. Weichselbaum, Theodore Karrison, Sean P. Pitroda, Olwen Hahn, Blase N. Polite, Hedy L. Kindler, Chih-Yi Liao, Ami V. Desai, Linda Janisch, Rita Nanda, Julia Dai, Mark J. Ratain, Gini F. Fleming
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research. 27(20)
Purpose: CD137 agonism and CSF1R blockade augment stereotactic body radiotherapy (SBRT) and anti-programmed death-1 in preclinical models. We evaluated the safety and efficacy of SBRT with nivolumab+urelumab (CD137 agonist) or nivolumab+cabiralizumab
Autor:
Kathy D. Miller, Rita Nanda, Vandana G. Abramson, Neelima Vidula, Ben Park, Hope S. Rugo, Minetta C. Liu, Adam Brufsky, Andrei Goga, Paula Pohlmann
Publikováno v:
Cancer Research. 80:OT2-04
Background: Chest wall recurrence can occur as a complication of breast cancer. This type of breast cancer is difficult to treat with short-lived responses to therapy, and associated with the development of distant metastases. Better therapies are ne
Autor:
Rachel Schiff, Mothaffar F. Rimawi, Matthew P. Goetz, Jorge S. Reis-Filho, Ting Wang, Britta Weigelt, Carolina Gutierrez, CK Osborne, Aleix Prat, Suzanne A. W. Fuqua, Antonio C. Wolff, R. Mao, Jamunarani Veeraraghavan, Andres Forero, Anna C. Pavlick, Paolo Nuciforo, Ingrid A. Mayer, C. De Angelis, SG Hilsenbeck, Jenny C. Chang, Ian E. Krop, Rita Nanda, Sabrina Herrera, Alejandro Contreras
Publikováno v:
Ann Oncol
BACKGROUND: HER2-positive (+) breast cancers, defined by HER2 overexpression and/or amplification, are often addicted to HER2 to maintain their malignant phenotype. Yet, some HER2+ tumors do not benefit from anti-HER2 therapy. We hypothesize that HER
Autor:
Kenji Tamura, Hirofumi Mukai, Vassiliki Karantza, Hope S. Rugo, Peter Schmid, Rita Nanda, Sylvia Adams, Anne C Armstrong, Sherene Loi, Deborah Toppmeyer, David W. Cescon, H. Iwata, Minetta C. Liu, Larisa Ryvo, Antoinette R. Tan, Y. Ding, Pauline Wimberger, M. De Laurentiis, L. Jia, EP Winer
Publikováno v:
Annals of Oncology. 30:405-411
Background Standard first-line treatment of metastatic triple-negative breast cancer (mTNBC) is chemotherapy. However, outcomes are poor, and new treatment options are needed. In cohort B of the phase II KEYNOTE-086 study, we evaluated pembrolizumab